Syn-Ake vs IGF-1 LR3
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Syn-Ake is a synthetic tripeptide that mimics waglerin-1, a peptide found in the venom of the Temple viper (Tropidolaemus wagleri). It acts as a reversible antagonist of muscular nicotinic acetylcholine receptors, temporarily reducing facial muscle contraction and smoothing dynamic wrinkles. Often called a 'synthetic Botox' in cosmetic marketing.
- IGF-1 LR3 is a synthetic analog of Insulin-like Growth Factor-1 with an extended half-life. It is one of the most potent anabolic peptides available, directly stimulating muscle cell hyperplasia and hypertrophy, and is the downstream mediator of many of GH's anabolic effects.
- Half-Life
- Not applicable (topical; effect duration hours)
- 20–30 hours
- Admin Route
- Topical
- SubQ, IM
- Research
- —
- —
- Typical Dose
- 0.01–0.1% (4–8 mg/g in clinical studies)
- 40–80 mcg
- Frequency
- Twice daily
- Once daily or split twice daily
- Key Benefits
- Reduces depth of dynamic wrinkles and expression lines
- Reversible muscle-relaxing effect on facial muscles
- Smooths forehead lines, crow's feet, and frown lines
- Non-invasive alternative to injectable neurotoxins
- Rapid onset relative to collagen-stimulating peptides
- Well-studied in in vitro and clinical cosmetic trials
- Direct muscle hypertrophy via IGF-1R stimulation
- Muscle hyperplasia (new fiber formation) — unique among peptides
- Rapid gains in lean muscle mass
- Accelerated recovery from training and injury
- Increased nutrient uptake by muscle cells
- Fat oxidation enhancement
- Bone density improvement
- Cartilage and connective tissue repair
- Side Effects
- Generally very well-tolerated topically
- Rare skin sensitivity or contact dermatitis
- Theoretical neuromuscular effects at systemic doses (not relevant topically)
- Hypoglycemia (significant risk — insulin-like activity)
- Acromegaly-like effects with excessive long-term use
- Jaw and hand swelling
- Organ hypertrophy with extreme doses
- +2 more
- Stacks With
- —
- —